Barely Significant
← all excerpts

The S1P receptor 1 antagonist Ponesimod reduces TLR4-induced neuroinflammation and increases Aβ clearance in 5XFAD mice.

EBioMedicine · 2023 · PMC10393615 · PMID 37480622

Europe PMCDOI
2
hedged sentences
0.0649
closest p · 1.3× alpha
0.0649
boldest claim

The sentences

showed a trendP = 0.0649so close (0.05 < p ≤ 0.1)
Ponesimod-treated 5XFAD mice showed a trend to an elevated number of the alternations for the unvisited arms as compared to the vehicle-treated 5XFAD mice ( Fig. 7 C, P = 0.0649).

also in 53,322 other papers

did not reach statistical significanceno p-value reported
Even though, the increase of AAR did not reach statistical significance, this result was consistent with the SAR data indicating that Ponesimod rescues attention/working memory in 5XFAD mice.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.